Table 1 Demographics and clinical features of participant groups at baseline
| Â | ERAN | BSRBR anti-TNF | BSRBR-Control | PPT study | Repeatability |
|---|---|---|---|---|---|
N= | 813 | 10,813 | 2992 | 45 | 34 |
%female | 70% | 76% | 74% | 77% | 73% |
Age (mean (sd)) | 57 (14) | 56 (12) | 60 (12) | 60 (11) | 60 (13) |
Seropositive | 59% | 65% | 58% | 90% | 79% |
DAS28-ESR | 5.2 (1.1) | 6.6 (1.0) | 5.4 (1.1) | 4.7 (0.9) | 4.8 (1.1) |
ESR | 34 (24) | 46 (29) | 37 (25) | 21 (13) | 39 (29) |
SJC | 7 (6) | 11 (6) | 6 (5) | 1 (1) | 5 (4) |
TJC | 9 (7) | 16 (7) | 9 (7) | 11 (7) | 6 (6) |
VAS-GH | 50 (24) | 73 (20) | 57 (23) | 53 (23) | 39 (20) |
CRP | 28 (37) | 46 (42) | 35 (40) | < 5 | not collected |